¡Ya estamos en ! Descubre más

Alkermes

ALKS

Capitalización de mercado USD 6915 M

41.22 USD

+1.12

2.79%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

41.40

+0.18

0.44%

1 día

2.79%

5 días

1.35%

1 mes

-10.53%

3 meses

-20.64%

6 meses

22.06%

En lo que va del año

45.86%

1 año

33.83%

5 años

36.04%

10 años

-2.71%

Acerca de: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Empleados: 2,050

Atención médica Fabricantes de medicamentos especializados y genéricos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 50%

Neutral 50%

Negativo 0%

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society's (ESRS) 28th Congress, Sleep Europe 2026, taking place Oct. 20-23, 2026 in Maastricht, the Netherlands. The company will present new data related to LUMRYZ® (sodium oxybate) extended-release oral suspension, now part of Alkermes' sleep portfolio following the acquisition.

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

Zacks Investment Research

4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.

4 CNS Drug Stocks Worth Watching This World Mental Health Day

Stock Picks From Seeking Alpha's September 2026 New Analysts

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.

Stock Picks From Seeking Alpha's September 2026 New Analysts

Zacks Investment Research

LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?

LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.

LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?

Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver

Alkermes is positioned for significant growth through LUMRYZ's potential expansion into idiopathic hypersomnia (IH), following positive Phase 3 results. LUMRYZ's IH indication could drive incremental revenue, leveraging existing commercial infrastructure and delivering operating leverage with a limited SG&A increase. ALKS faces a 10% royalty to Jazz Pharmaceuticals on non-narcolepsy LUMRYZ sales post-March 2028, but the opportunity remains financially meaningful.

Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver

Zacks Investment Research

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

Investors Business Daily

How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won

Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD.

How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD). The study evaluated the safety and tolerability (primary objective) and pharmacokinetics (PK) and pharmacodynamics (PD) of ALKS 7290 in healthy volunteers (n=88) and in adults with ADHD (n=5.

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company's Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings deep commercial and operational expertise, as well as a proven track record of driving growth and transformation across global pharmaceutical and biotechnology organizations. “Anne joins our Board at a defining time for.

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise

Alkermes plc is upgraded from Hold to Buy, driven by robust revenue growth, pipeline momentum, and strategic positioning in sleep and CNS disorders. Acquisition of Avadel and Lumryz launch propel >20% revenue growth in 2026; adjusted EBITDA guidance is $370–410M despite a GAAP net loss. Alixorexton's strong Phase 2 data in narcolepsy and IH, plus advancing orexin pipeline, underpin multi-billion-dollar long-term revenue potential.

Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™